CD274 and hepatocellular carcinoma: These findings indicate that the combination of GO-PEI-PEG delivering PD-L1 siRNAs with oral sorafenib can stimulate adaptive immunity and tumor ferroptosis, offering a promising treatment for advanced HCC patients.